New Therapeutic Approaches to Combat Arterial Thrombosis
Figure 3
Structures for the reversible P2Y12 antagonists currently in clinical trials
The varied structures of (A) ticagrelor, (B) cangrelor, and (C) elinogrel are shown. All three drugs share the same molecular target, the platelet P2Y12 receptor.
